Image Credit: STAT News
STAT+: Pharmalittle: We’re reading about the end of a Lilly drug shortage, a Novo obesity trial disappointment, and more
Novo Nordisk’s next-generation obesity candidate led to substantial weight loss in a pivotal study but fell short of expectations